Daily amifostine given concomitantly to chemoradiation in head and neck cancer. A pilot study

Strahlentherapie und Onkologie

Volumn 175, Issue 9, 1999, Pages 444-449

  Trog, Daniela ^a   Bank, Priska ^a   Wendt, Thomas G ^a,b   Koscielny, Sven ^a   Beleites, Eggert ^a  

^a FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^b JENA UNIVERSITY HOSPITAL   (Germany)

Author keywords

Amifostine; Chemoradiation; Head and neck neoplasm; Mucositis

Indexed keywords

AMIFOSTINE; FLUOROURACIL;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEAD CANCER; HUMAN; HYPOCALCEMIA; LEUKOPENIA; MALE; MUCOSA INFLAMMATION; NECK CANCER; SURVIVAL RATE; TREATMENT OUTCOME;

ADULT; AGED; AMIFOSTINE; CARCINOMA, SQUAMOUS CELL; COHORT STUDIES; COMBINED MODALITY THERAPY; DOSE FRACTIONATION; FEMALE; HUMANS; MALE; MIDDLE AGED; MOUTH MUCOSA; NEOPLASM STAGING; OTORHINOLARYNGOLOGIC NEOPLASMS; PILOT PROJECTS; PREMEDICATION; RADIATION INJURIES; RADIATION-PROTECTIVE AGENTS; STOMATITIS; SURVIVAL RATE;

EID: 0032869335     PISSN: 01797158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s000660050034     Document Type: Article

References (22)

1. Antonadou D, Pepelassi E, Synodinou M, et al. The prophylacic use of amifostine in the prevention of chemoradiation induced mucositis and xerostomia. Int J Radiat Oncol Biol Phys 1998;42:Suppl 1:224.abstract 1031.
2. Bohuslavizki KH. Salivary gland protection by amifostine in high-dose radioiodine therapy of differentiate thyroid cancer. Strahlenther Onkol 1999;175:57-61.
3. Brizel D, Sauer R, Wannenmacher M, et al. Randomized phase III trial of radiation +-Ethyol (Amifostine) in patients with head and neck cancer. Int J Radiat Oncol Biol Phys 1998;42:Suppl 1:224.abstract 1032.
4. Byfield JE, Calabro-Jones P, Klisak I, et al. Pharmacologic requirements for obtaining sensitization of human tumor cells in vitro to combined 5-Fluorouracil or ftorafur and x-rays. Int J Radiat Oncol Biol Phys 1982;8:1923-33.
5. Capizzi RL, Oster W Protection of normal tissue from the cytotoxic effects of chemotherapy and radiation by amifostine: Clinical experiences. Eur J Cancer 1995;31 A:Suppl 1,S8-13.
6. Doz F, Berens ME, Spencer DR, et al. Experimental basis for increasing the therapeutic index of carboplatin in brain tumor therapy by pretreatment with WR 2721 compounds. Cancer Chemother Pharmacol 1991;28:308-10.
7. Fletcher GH. Textbook of radiotherapy, 3rd edn. Philadelphia: Lea & Febiger, 1980.
8. Glick JH, Glover D, Weiler C, et al. Phase I controlled trials of WR 2721 and cyclophosphamide. Int J Radiat Oncol 1984;10:1777-80.
9. Kemp G, Rose P, Lurain J, et al. Amifostine pretreatment for protection against cyclophasphamide-induced and cisplatin-induced toxicities: Results of a randomized control trial in patients with advanced ovarian Cancer. J Clin Oncol 1996;14:2101-12.
10. Kligerman MM, Liu T, Liu Y, et al. Interim analysis of a randomized trial of radiation therapy of rectal cancer with/without WR 2721. Int J Radiat Oncol Biol Phys 1992;22:799-802.
11. Leibel SA, Scott CB, Mohiuddin M, et al. The effect of loco-regional control on distant metastatic dissemination in carcinoma of head and neck: Results of an analysis from the RTOG hed and neck database. Int J Radiat Oncol Biol Phys 1991;21:549-56.
12. Lo TCM, Wiley AL Jr, Ansfield FJ, et al. Combined radiation therapy and 5-fluorouracil for advanced squamous cell carcinoma of the oral cavity and oropharynx: A randomized study. AJR 1976;126:229-35.
13. McDonald S, Meyerowitz C, Smudzin T, et al. Preliminary results of a pilot study using WR 2721 before fractionated irradiation of the head and neck to reduce salivary gland dysfunction. Int J Radiat Oncol Biol Phys 1994;29:747-54.
14. Rasey JS, Krohn KA, Menard TW, et al. Comparative biodistribution and radioprotection studies with three radioprotective drugs in moues tumours. Int J Radiat Oncol Biol Phys 1986;12:1487-90.
15. Sanchíz F, Millá A, Torner J, et al. Single fraction per day versus two fractions per day versus radiotherapy in the treatment of head and neck cancer. Int J Radiat Oncol Biol Phys 1990;19:1347-50.
16. Seegenschmiedt MH. Nebenwirkungen in der Onkologie. Berlin: Springer, 1998.
17. UICC. TNM-Klassifikation maligner Tumoren, 5. Aufl. Berlin: Springer, 1995.
18. Wasserman TH, Phillips TL, Ross G, et al. Differential protection against cytotoxic chemotherapeutic effects on bone marrow CPUs. Cancer Clin Trials 1981;4:3-6.
19. Wibault P, Bensmaine MA, de Forni M, et al. Intensive concomitant chemoradiotherapy in locally advanced unresectable squamous cell carcinoma of the head and neck: a phase II study of radiotherapy with cisplatin and 7-week continuous infusional fluorouracil. J Clin Oncol 1996;14:1192-200.
20. Yuhas JM. Active versus passive absorption kinetics as the basis for selective protection of normal tissues by S-2-(3-aminopropylamino)-ethylphosphorothioic acid. Cancer Res 1980;40:1591-624.
21. Yuhas JM, Spellman JM, Culo F. The role of WR 2721 in radiotherapy and/or chemotherapy. Cancer Clin Trials 1980;3:211-6.
22. Zbaeren P, Lehmann W. Frequency and sites of distant metastases in head and neck squamous cell carcinoma. An analysis of 101 cases at autopsy. Arch Otolaryngol Head Neck Surg 1987;113:724-62.